Category: 50998-17-9

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

50998-17-9, After adding 6-bromoquinoxaline (3.8 g, 18.2 mmol), n-butyl vinyl ether (12.3 mL, 95.2 mmol), potassium carbonate (3.1 g, 22.8 mmol), 1,3-bis(diphenylphosphino)propane (504 mg, 1.3 mmol) and palladium(II) acetate (124 mg, 0.5 mmol) to N,N-dimethylformamide (47 mL) and water (6 mL), the result was stirred and refluxed for 6 hours. After terminating the reaction, the result was cooled to room temperature, 2 N hydrochloric acid was added thereto, and the result was stirred for 0.5 hours. Ethyl acetate was added thereto, the organic layer was washed with water and sodium bicarbonate, dried using anhydrous magnesium sulfate, and filtered. The filtrate was concentrated and purified using column chromatography to obtain a target compound (2.4 g). 1H NMR spectrum (300 MHz, DMSO-d6) delta 10.05(d, 1H), 9.73(t, 1H), 8.71(s, 1H), 7.97(d, 1H), 3.16(s, 3H).

50998-17-9 6-Bromoquinoxaline 610939, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; Hanmi Pharmaceutical Co., Ltd.; LEE, Kyung Ik; JUNG, Young Hee; SONG, Ji Young; JUN, Seung Ah; (89 pag.)EP3480193; (2019); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.,50998-17-9

To a solution of 6-bromoquinoxaline (500 mg, 2.39 mmol, 1 eq.) in 1,4-dioxane (10 mL) was added 5-(4,4,5,5-Bis(pinacolato)diboron (729 mg, 2.87 mmol, 1.2 eq.), KOAc (469 mg, 4.78 mmol, 2 eq.), and PdCl2dppf?DCM complex (195 mg, 0.23 mmol, 0.1 eq.). The reaction mixture was deoxygenated with N2 allowed stir at 80 C. for 18 h. The reaction mixture was cooled to RT, diluted with water (50 mL) and extracted with ethyl acetate (2*50 mL). Combined organic layer was washed with brine (20 mL) and dried over sodium sulfate. Removal of solvent under reduced pressure gave crude which was purified by normal phase Combi-flash column chromatography (0-100% EtOAC-Hexane) to afford quinoxalin-6-ylboronic acid (350 mg, 85%) as brown oil.

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; GiraFpharma LLC; PHAM, Son Minh; CHEN, Jiyun; ANSARI, Amantullah; JADHAVAR, Pradeep S.; PATIL, Varshavekumar S.; KHAN, Farha; RAMACHANDRAN, Sreekanth A.; AGARWAL, Anil Kumar; CHAKRAVARTY, Sarvajit; (120 pag.)US2019/23666; (2019); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

To a solution of 11c (50 mg, 215 mumol), 6-bromoquinoxaline (66.9 mg, 320 mumol), Bu4NOAc (129 mg, 428 mumol) and Pd(OAc)2 (7.24 mg, 32.2 mumol) in NMP (0.5 mL ). The reaction mixture was stirred for 15 h at 100 oC and cooled to room temperature. The mixture was concentrated under reduced pressure, diluted with water, and extracted with EtOAc (3 ¡Á 5 mL). The EtOAc solution was washed with brine (5 mL), dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (1:1 hexane/EtOAc) to afford the compound 12c (17 mg, 22%) as a yellow solid. TLC: Rf 0.22 (1:1 MeOH/CH2Cl2). 1H-NMR (400 MHz, CDCl3) delta 8.90 (d, 2H, J = 4.4 Hz), 8.09 (s, 1H), 8.08 (d, 1H, J = 8.0 Hz), 7.73 (t, 1H, J = 8.0 Hz), 7.63-7.60 (m, 2H), 7.13 (d, 1H, J = 8.0 Hz), 3.65 (t, 2H, J = 6.4 Hz), 2.85 (t, 2H, J = 7.6 Hz), 2.20 (s, 3H), 1.88 (quintet, 2H, J = 7.6 Hz), 1.65 (m, 2H), 1.58 (brs, 1H). 13C-NMR (100 MHz, CDCl3) delta 158.3, 149.2, 147.3, 145.8, 145.7, 142.8, 142.7, 139.1, 132.8; 132.1, 130.9, 130.4, 129.2, 123.6, 115.2, 62.4, 32.3, 25.7, 24.7, 23.8. HRMS (ESI) calcd. for C20H21N6O (M+H): 361.1771; found 361.1771.

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Article; Li, Fei; Park, Yunjeong; Hah, Jung-Mi; Ryu, Jae-Sang; Bioorganic and Medicinal Chemistry Letters; vol. 23; 4; (2013); p. 1083 – 1086;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

INTERMEDIATE 216-(2-Chloropyridin-4-yl)quinoxalineA mixture of 6-bromoquinoxaline (1.07 g, 5.14 mmol), 2-chloropyridine-4- boronic acid (810 mg, 5.14 mmol), 2M aqueous sodium carbonate solution (5.5 mL, 11 mmol) and Pd(PPh3)4 (178 mg, 0.15 mmol) in DME (11 mL) was heated to 1200C in a sealed tube, under microwave irradiation, for 20 minutes. After cooling, the mixture was partitioned between water and EtOAc (100 mL each). The aqueous phase was extracted with EtOAc/THF (4: 1, 50 mL). The combined organic phases were dried (MgSO4) and concentrated in vacuo. The residue was washed with diethyl ether/THF (9: 1, 30 mL) to give the title compound (790 mg, 64%) as a brown solid. deltaH (CDCl3) 8.89-8.97 (m, 2H), 8.54 (d, IH), 8.39 (d, IH), 8.26 (d, IH), 8.03 (dd, IH), 7.72 (s, IH), 7.60 (dd, IH). LCMS (ES+) 242 (M+H)+, RT 2.87 minutes., 50998-17-9

50998-17-9 6-Bromoquinoxaline 610939, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; UCB PHARMA S.A.; BUeRLI, Roland; HAUGHAN, Alan, Findlay; MACK, Stephen, Robert; PERRY, Benjamin, Garfield; RAPHY, Gilles; SAVILLE-STONES, Elizabeth, Anne; WO2010/52448; (2010); A2;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.,50998-17-9

Take 1mmol cp-2-19,Dissolved in 10ml anhydrous acetonitrile,0.05 mmol of Pd (OAc) 2,0.1 mmol of P (O-Tolyl) 3 and 3 mmol of Et3N were added,Then add 1.5mmol 6-bromoquinoxaline, Ar gas protection reaction 12h, after the reaction filter,After the filtrate was evaporated to dryness, the methylene chloride was dissolved, washed with water, washed with saturated NaCl, treated with anhydrous MgSO4,Silica gel column (PE: EA 50: 1) to give the compound

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Peking University; Fu, Hongzheng; Chen, Peng; (29 pag.)CN106543032; (2017); A;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

50998-17-9, A solution containing 6-bromo-quinoxaline (417 mg, 2.0 mmol), 4-(4 ,4,5,5- tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert- butyl ester (600 mg, 1.94 mmol), tetrakis [triphenylphosphine] palladium (108 mg, 0.1 mmol) and sodium carbonate (2 M solution, 3 ml_) in 5 ml_ of dioxane/ethanol/water (7:3:1 ) was heated at 160 C using microwave reactor for 15 minutes. After the reaction, ethylacetate was added and the mixture was filtered, washed with water. After concentration under vacuum, the product was purified using column chromatography (5% methanol in dichloromethane)

50998-17-9 6-Bromoquinoxaline 610939, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; SCHERING CORPORATION; WO2008/153858; (2008); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

50998-17-9, 6-Bromo quinoxaline (2.0 g, 9.5 mmol) in toluene (20 ml.) was degassed for 30 min. To this solution, 1-ethoxy vinyl tributyltin (3.8 g, 10.5 mmol) and bis(triphenylphosphine)palladium dichloride (0.67 g, 0.95 mmol) were added at rt and stirred for 16 hours at 90 C. The reaction mixture was cooled to rt and filtered through celite. After evaporation of the solvent, 6 N HCl solution in water (20 ml.) was added and the mixture was stirred for 1 hour at rt. It was concentrated and neutralized with sat. NaHCO3. The desired product was extracted with DCM (100 mL,), dried over Na2SO4 and concentrated. The crude product was purified by flash column chromatography to afford the title compound (brown solid). 1H NMR (400 MHz, DMSO-d6): delta 9.06-9.04 (m, 2H), 8.70 (d, J=2.4 Hz, 1H), 8.28 (t, J = 2.8 Hz, 1H), 8.16 (d, J = 11.6 Hz, 1H), 2.97 (s, 3H). LCMS: (Method A) 173 (M+H), Rt. 2.25 min, 99.06% (Max).

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Patent; ASCENEURON SA; QUATTROPANI, Anna; KULKARNI, Santosh S.; GIRI, Awadut Gajendra; (243 pag.)WO2016/30443; (2016); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

A degassed mixture of the crude 3-(3-pyrrolidin-1-yl-prop-1-ynyl)-2-trimethylstannanyl-imidazo[1,2-a]pyridine-6-carboxylic acid bis-(3-methyl-butyl)amide (ca. 262 mg) and 6-bromoquinoxaline (96 mg) in DMF (3 ml) was treated with Pd(PPh3)4 (48 mg). The reaction mixture was transferred to a pre-heated oil bath (110C) and stirred in a sealed tube at this temperature for 18 h. The mixture was diluted with diethyl ether (25 ml) and washed with water (1 x 20 ml). The aqueous layer was extracted with diethyl ether (2 x 15 ml). The combined organic extracts were washed with brine (30 ml), dried over sodium sulfate, filtered, and evaporated. The crude product was isolated by column chromatography and re-purified by preparative HPLC-MS., 50998-17-9

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Patent; Santhera Pharmaceuticals (Schweiz) AG; EP2168965; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

50998-17-9, General procedure: In round bottom flask, added 12a (100mg, 0.5mmol) followed by 47 4-bromo-1,2-(methylenedioxy)benzene (0.45mmol), 13 PdCl2(PPh3)2 (5mol%) and 48 KOAc (0.5mmol) sequentially in dry 49 DMA (10ml). The reaction mixture was stirred at 150C for 18h. The reaction mixture was diluted with saturated NaHCO3 and extracted with EtOAc. The organic layer dried over Na2SO4, filtered and evaporated to give crude product which was finally purified by column chromatography to afford 50 13a.

50998-17-9 6-Bromoquinoxaline 610939, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Article; Karale, Uttam B.; Krishna, Vagolu Siva; Krishna, E. Vamshi; Choudhari, Amit S.; Shukla, Manjulika; Gaikwad, Vikas R.; Mahizhaveni; Chopra, Sidharth; Misra, Sunil; Sarkar, Dhiman; Sriram, Dharmarajan; Dusthackeer, V.N. Azger; Rode, Haridas B.; European Journal of Medicinal Chemistry; vol. 178; (2019); p. 315 – 328;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

6-Bromo quinoxaline (2.0 g, 9.5 mmol) in toluene (20 ml.) was degassed for 30 min. To this solution, 1-ethoxy vinyl tributyltin (3.8 g, 10.5 mmol) and bis(triphenylphosphine)palladium dichloride (0.67 g, 0.95 mmol) were added at rt and stirred for 16 hours at 90 C. The reaction mixture was cooled to rt and filtered through celite. After evaporation of the solvent, 6 N HCl solution in water (20 ml.) was added and the mixture was stirred for 1 hour at rt. It was concentrated and neutralized with sat. NaHCO3. The desired product was extracted with DCM (100 mL,), dried over Na2SO4 and concentrated. The crude product was purified by flash column chromatography to afford the title compound (brown solid). 1H NMR (400 MHz, DMSO-d6): delta 9.06-9.04 (m, 2H), 8.70 (d, J=2.4 Hz, 1H), 8.28 (t, J = 2.8 Hz, 1H), 8.16 (d, J = 11.6 Hz, 1H), 2.97 (s, 3H). LCMS: (Method A) 173 (M+H), Rt. 2.25 min, 99.06% (Max)., 50998-17-9

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ASCENEURON SA; QUATTROPANI, Anna; KULKARNI, Santosh S.; GIRI, Awadut Gajendra; (243 pag.)WO2016/30443; (2016); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider